Viatris Views Ophthalmology, Dermatology, and Gastroenterology as Future Pipeline Focus

Equity Analyst

Keonhee Kim

Revenue segments as reported by the company.

Brands

Complex Gx and Biosimilars

Generics

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Litigation settlements and other contingencies, net

Acquired IPR&D

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Viatris is one of the largest generic drug manufacturers in the world. Viatris' generics business makes up roughly 40% of company's sales and, along with other generics manufacturers, it continues to suffer low- to mid-single-digit erosion year over year in developed markets like North America and the majority of Europe. Because price and margin 

headwinds exist predominantly in small-molecule oral tablets that are easy to produce, we expect Viatris’ future pipeline to focus more on complex generics—drugs that have complex formulations, dosage forms, or are injected or have more complex administration. 

Complex generics are more difficult to manufacture which by nature limits competition. And since price, volume, and margin are highly dependent on the competitiveness of a drug, complex generics pave an opportunistic road for Viatris. But other players in the industry are employing a similar strategy so success in this area relies on the company’s ability to seek out profitable drugs and efficiently launching them to market.

The remaining 60% of Viatris’ sales is derived from off-patent branded drugs, including Lipitor, Lyrica, and Norvasc. While macrotrends like the aging population and growing emerging markets can continue to boost sales, we still expect low- to mid-single-digit erosion in the business from pricing and volume headwinds driven from more patients opting generic versions. To combat this, Viatris has identified ophthalmology, dermatology, and gastroenterology as three key therapeutic areas of focus for future innovations. Since these areas are all specialty-driven, a small salesforce can capture a large number of doctors. And a lot of innovations usually come from smaller players, meaning there is not one big leader that Viatris has to displace to gain shares. It launched Tyrvaya, the first and only nasal spray 

for the treatment of dry eye disease at the time of launch, and it expects additional products for dry eye disease going forward. In 2023, it acquired Oyster Point and Famy Life Sciences, two companies that focus on ophthalmology, and we expect additional small tuck-in acquisitions in the three therapeutic areas to fuel its pipeline.

Business Strategy & Outlook

We assign Viatris a no-moat rating because we do not believe the company possesses any structural advantages strong enough to earn excess returns and generate return on invested capital above its cost of capital over the next 10 years. 

While generic drugs were around in the U.S. since the early 20th century, their industry experienced a significant growth following the passage of the 1984 Hatch-Waxman Act. The legislation facilitated the drug application process for generic drug manufacturers by providing them a safe harbor from patent infringement litigation from branded drug manufacturers and allowed the U.S. Food and Drug Administration to approve applications for generic drugs with abbreviated new drug applications. An ANDA requires the applicant to demonstrate its generic drug’s pharmaceutical equivalence and bioequivalence to the reference drug, but it generally does not require preclinical and clinical data to prove safety and effectiveness since it relies on the FDA’s prior approval of the reference drug’s safety and effectiveness. Overall, this legislation paved a much swifter way for generics manufacturers to get their drugs approved compared with a new drug application, which a new branded drug must go through.

The U.S. generic drug industry enjoyed another boost when Congress enacted a series of amendments named the Generic Drug User Fee Amendments (first one passed in 2012, second in 2017 and the latest in 2022), allowing the FDA to collect fees from ANDA applicants to expedite application approval process. The fees (an ANDA fee rate for 2023 was around $240,000) are not meaningful to sway big generic manufacturers away and they also provide additional revenue streams and financial support to the FDA, allowing applications to be approved more quickly and efficiently. 

These regulatory pushes by the U.S. government paved ways for the industry to be highly competitive and be filled with commoditized products, eroding a lot of pricing power that generics manufacturers once had. And although there are a few number of players that make up a relatively healthy share of the generics market, barriers to entry here is quite low, expanding possibilities for firms in the space to face additional competition going forward. This explains the hike in generic dispensing rate (percentage of prescriptions dispensed with a generic rather than a branded reference drug) which grew from 54% to 91% between 2002 and 2019. And while an average of less than 300 ANDAs were approved annually from 1985 to 2012, thanks to these changes, the FDA has averaged around 1,000 ANDA approvals per year over the last five years. 

Beyond government actions, generics manufacturers also face pressures from players within the drug supply chain. The formation of powerful generic sourcing groups and establishment of generic formularies by pharmacy benefit manager enabled drug distributors and drug buyers to effectively negotiate lower generic prices, hurting manufacturers’ margins.

Three large generic sourcing programs that were formed as joint ventures between large wholesalers and drug purchasers—ClarusONE (2016, McKesson and Walmart); Red Oak Sourcing (2013, Cardinal Health and CVS); and Walgreens Boots Alliance Development (2012, AmerisourceBergen and Walgreens)—have acted as additional headwind for generics manufacturers. These entities were created to lower generics acquisition costs through the aggregation of purchasing power and as a result, they can demand higher buy-side discounts and rebates from generics manufacturers, ultimately eating into their profits. They now purchase roughly 80% of all generics sold in the U.S. Additionally, the interchangeability between generics has facilitated the establishment of generic formularies, in which wholesalers can use their purchasing scale to negotiate deeper concessions for placement in the generic sourcing program. As these three players continue to make up a larger portion of generic sourcing in the country and enhance their buying power, generics manufacturers are left with no other choice but to face the burden, resulting in low- to mid-single-digit price erosion in the market year over year.

By our estimate, roughly 40% and 50% of Viatris total sales are derived from generics and off-patent branded drugs, respectively, and both areas are highly susceptible to all the pricing headwinds mentioned above. Viatris has decided to combat this by rationalizing and optimizing its portfolio, carefully deciding which drugs to continue commercializing and which drugs to discontinue. The company opted to exit spaces where it had too many existing players and discontinue small-molecule drugs that are fairly simple to be FDA-approved and to be replicated. Furthermore, Viatris has continued to pursue more opportunities into branded drugs, aiming to launch sizable novel drugs that can have a meaningful impact on the top and bottom lines. Viatris has also sought to expand its presence in complex generics. These drugs typically face limited competition due to a more complicated level of research and development required before reaching commercial stage. Instead of being available in simple oral tablets, which are relatively easy to replicate by competitors, complex generics and biosimilars usually come in injectables, inhalers, and other different forms that pose more challenges to other manufacturers to produce. 

Despite these efforts, we don’t believe Viatris has any structural advantages over other generic manufacturers. It doesn’t have a meaningfully larger number of first-to-file launches compared with other players in the space. And even if it launches a few drugs that are first to market and gain 180-day exclusivity periods in certain products, they are likely to face direct competition as soon as that period expires, leading to significant volume reductions. If Viatris continues to downsize its portfolio of commoditized and easy-to-replicate generic drugs and replace them with more innovative medicines, we could potentially revisit our analysis. For now, we do not believe Viatris earns a moat rating.

None

Economic Moat

Viatris

Viatris, Inc. is a global healthcare company, which engages in the provision of access to medicines and sustainable operations. It also offers support services such as diagnostic clinics, educational seminars, and digital tools. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan and Hong Kong. The JANZ segment consists of operations in Japan, Australia and New Zealand. The Emerging Markets segment encompasses operations with developing markets and emerging economies including countries in Asia, the Middle East, South and Central America, Africa and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ares Capital

Crown Castle International

Golub Capital BDC

Vitesse Energy Inc

Warren Buffett owns five stocks with dividend yields of 4.9% or higher. Four of the five belong to the portfolio of one of Berkshire Hathaway's subsidiaries.

Warren Buffett Owns These 5 High-Yield Dividend Stocks. Should You?

NEW YORK , June 16, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Viatris, Inc. ("Viatris" or the "Company") (NASDAQ: VTRS), and certain officers.  The class action, filed in the United States District Court for the Western District of Pennsylvania and docketed under 23-cv-01098, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Viatris common stock between March 1, 2021 and February 25, 2022, inclusive (the "Class Period"), seeking remedies under the Securities Exchange Act of 1934 (the "Exchange Act").

Pomerantz Law Firm Announces the Filing of a Class Action Against Viatris, Inc. and Certain Officers - VTRS

Viatris remains a dirt cheap stock in a frothy market and pays a well-covered dividend yield. It continues to make progress towards deleveraging, and could return substantial capital to shareholders in 2024. With market sentiment working against the stock, it could deliver potentially strong total returns for investors should the tide change.

Viatris: Won't Take Much To Move The Needle

NEW YORK , June 13, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. (NASDAQ: VTRS) between March 1, 2021 and February 25, 2022, both dates inclusive (the "Class Period"), of the important July 14, 2023 lead plaintiff deadline. SO WHAT: If you purchased Viatris common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, LEADING INVESTOR COUNSEL, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS

Viatris Inc. (NASDAQ:VTRS ) Goldman Sachs 44th Annual Global Healthcare Conference June 13, 2023 4:20 PM ET Company Participants Scott Smith - CEO Rajiv Malik - President Sanjeev Narula - CFO Conference Call Participants Nathan Rich - Goldman Sachs Nathan Rich Great. Well, good afternoon, everyone.

Viatris Inc. (VTRS) Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)

NEW YORK--(BUSINESS WIRE)---- $VTRS #classaction--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Western District of Pennsylvania on behalf of those who acquired Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) securities during the period from March 1, 2021 through February 25, 2022 (the “Class Period”). Investors have until July 14, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Viatris is a global he.

Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of Viatris, Inc. (VTRS) Investors and Encourages Investors to Contact the Firm Before July 14, 2023

NEW YORK , June 10, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) and reminds investors of the July 14, 2023 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. If you suffered losses exceeding $100,000 investing in Viatris stock or options between March 1, 2021 and February 25, 2022 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext.

VIATRIS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Viatris To Contact Him Directly To Discuss Their Options

Enbridge

Viatris generates ample cash flow to pay down its debt and support its above-average dividend yield. Enbridge's payout ratio based on net income may look alarming, but the company's dividend is safer than it looks.

These 2 Dividend Stocks Yield 5% -- and They Aren't Risky Buys

NEW YORK , June 7, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. (NASDAQ: VTRS) between March 1, 2021 and February 25, 2022, both dates inclusive (the "Class Period"), of the important July 14, 2023 lead plaintiff deadline. SO WHAT: If you purchased Viatris common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS

Viatris (VTRS) reported earnings 30 days ago. What's next for the stock?

Why Is Viatris (VTRS) Down 2.4% Since Last Earnings Report?

American Airlines

Comerica

General Motors

Lincoln National

NRG Energy

Organon & Co

United Continental Hlds

Valero Energy

Why deal with the S&P 500 when savings accounts pay 5%? That's exactly why many rich people are dumping stocks for cash.

9 S&P 500 Stocks Are Screaming Buys According To The 'Fed Model'

NEW YORK , June 5, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS). Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viatris Inc. - VTRS

Pfizer

High-quality dividend stocks typically aren't cheap. Viatris has a great roster of medicines on the market, with more generics to come.

Looking for Passive Income at a Decent Price? Buy These 2 Stocks

Did you lose money on investments in Viatris?  If so, please visit Viatris Inc. Shareholder Class Action Lawsuit or contact  Peter Allocco at (212) 951-2030 or pallocco@bernlieb.com to discuss your rights.

VIATRIS INC. (NASDAQ: VTRS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Viatris Inc.

NEW YORK , May 31, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. (NASDAQ: VTRS) between March 1, 2021 and February 25, 2022, both dates inclusive (the "Class Period"), of the important July 14, 2023 lead plaintiff deadline. SO WHAT: If you purchased Viatris common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

VTRS INVESTOR NEWS: TOP RANKED ROSEN LAW FIRM Encourages Viatris Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - VTRS

STOCKHOLM , May 31, 2023 /PRNewswire/ -- InDex Pharmaceuticals Holding AB (publ) ("InDex") today announced that a license agreement has been signed with Viatris Pharmaceutical Japan Inc. ("Viatris Japan") to register and commercialize cobitolimod in Japan for the treatment of ulcerative colitis. Cobitolimod is a TLR9 agonist which is being evaluated in the global phase III program CONCLUDE, as a novel treatment for moderate to severe ulcerative colitis.

InDex Pharmaceuticals announces license agreement with Viatris Japan to develop and commercialize cobitolimod in Japan

RADNOR, Pa. , May 30, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Pennsylvania against Viatris Inc. ("Viatris") (NASDAQ:VTRS).

KESSLER TOPAZ MELTZER & CHECK, LLP ANNOUNCES A SECURITIES FRAUD CLASS ACTION FILED AGAINST VIATRIS INC. (VTRS)

PITTSBURGH , May 30, 2023 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has been named to USA Today's inaugural list of America's Climate Leaders 2023 for companies that have demonstrated the greatest reduction in emissions intensity. The list was compiled by USA Today and market research company Statista, the world-leading statistics portal and industry ranking provider.

Viatris Named to USA Today's Inaugural List of America's Climate Leaders 2023

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Western District of Pennsylvania against Viatris Inc. (“Viatris”) (NASDAQ:VTRS). The action charges Viatris with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a resul.

Securities Class Action Reminder (NASDAQ: VTRS): Kessler Topaz Meltzer & Check, LLP Reminds Viatris Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)---- $VTRS #BioconBiologicsLimited--Viatris Inc. (VTRS) Misled Investors Regarding its Business Prospects.

Viatris Inc. (VTRS) Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Viatris Inc. Securities Class Action

Kirby McInerney LLP Announces the Filing of a Securities Class Action on Behalf of Viatris, Inc. (VTRS) Investors

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming July 14, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) common stock between March 1, 2021 and February 25, 2022, inclusive (the “Class Period”). If you suffered a loss on your Viatris investments or would like to inquire about potentially pursuing claim.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Viatris Inc. (VTRS)

LE AD PLAINTIFF DEADLINE IS JULY 14, 2023 NEW YORK , May 25, 2023 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") announces that a federal securities class action lawsuit has been filed in the United States District Court for the Western District of Pennsylvania on behalf of persons and entities that purchased or otherwiseacquired Viatris Inc. ("Viatris" or the "Company") (NASDAQ: VTRS) common stockbetween March 1, 2021 and February 25, 2022, inclusive (the "Class Period"). A ll investors who purchased shares and incurred losses are advised to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.

VIATRIS INC. CLASS ACTION ALERT: WOLF HALDENSTEIN ADLER FREEMAN & HERZ LLP REMINDS INVESTORS THAT A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF PENNSYLVANIA AGAINST VIATRIS INC.

NEW YORK , May 24, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Viatris Inc. (NASDAQ: VTRS) between March 1, 2021 and February 25, 2022, both dates inclusive (the "Class Period"), of the important July 14, 2023 lead plaintiff deadline. SO WHAT: If you purchased Viatris securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A RESPECTED AND LEADING FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - VTRS

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming July 14, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Viatris Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) common stock between March 1, 2021 and February 25, 2022, inclusive (the “Class Period”). Investors suffering losses on their Viatris investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal right.

News for Viatris Stock (VTRS)